Abstract: Therapeutically active anthranilic acid derivatives of Formula (I), processes for the preparation of said derivatives, pharmaceutical formulations containing the compounds and the use of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or in which activation of the receptor will be beneficial, are disclosed.

Abstract: The present invention provides therapeutically active compounds which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial, having the formula (II): wherein R1 is selected from: hydrogen and C1-4 alkyl which may be optionally substituted with one or more groups selected from CN and CF3, R2 is selected from: C2-10 unsubstituted alkyl, C1-10 alkyl substituted with one or more groups selected from fluorine and CN, C5 alkenyl, unbranched C4 alkenyl, and C1-4 alkyl substituted with cycloalkyl, and R3 is selected from halogen and CN.

Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atheroscelerosis.

Abstract: Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.

Abstract: The present invention relates to novel compounds and pharmaceutically acceptable derivatives thereof. The invention also relates to processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and to the use of compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

Abstract: Compounds of the formula (I) are inhibitors of the enzyme Lp-PLA2? and are of use in therapy, in particular for treating atherosclerosis.

Abstract: Pyrimidone and pyridone compounds of the formula: are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.

Abstract: Compounds of the formula (I) are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.

Abstract: Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis. Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.

Abstract: A sampler apparatus for unit dose bulk material sampling comprising an elongated housing having a first bore extending therethrough and a moveable piston rod extending through the first bore forming a sampling cavity between the front surface of the piston rod and the front end of the housing. A closure cap is attached to the front end of the housing and is adapted to selectively open and close the entrance to the sampling cavity. Also included are adjusting means for adjusting the size of the sampling cavity and compacting means for compacting the sample while the sample is contained within the sampling cavity.

Abstract: Apparatus for removing a sample of granular or powder materials from a vat in which such materials are mixed in bulk, including an elongated probe having a sample receiving cavity at one end which may be adjusted to a predetermined volume. The probe is inserted in the bulk mixture to a predetermined depth, the cavity loaded with material from the bulk and after closing the cavity, the probe is removed from the bulk removing therefrom a sample of a desired predetermined quantity representative of the bulk mixture at the insertion point. A backing plate is also provided in the probe to compact the sample in the cavity to facilitate handling of the sample.